Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ronald Kubica (NPI 1275532970)

Field	Value
Entity Type	Individual
Organization	Ronald Kubica
Address	4901 Lang Ave Ne
City	Albuquerque
State	NM
ZIP	87109
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 15, 2005

Payer Source	Total Paid
Medicare	$1M
Medicaid	$0

Key Findings

The provider’s code mix is consistent with an infusion-centered medical oncology practice: the top billed drug is pembrolizumab (J9271: 12.6K claims, $541.8K revenue) and multiple chemotherapy administration codes appear in the top 25 (96413, 96401, 96417, 96415, 96365/96367), alongside supportive biologics such as denosumab (J0897) and immune globulin (J1569). This pattern indicates routine outpatient delivery of systemic cancer therapies and associated office-based management rather than a radiation- or procedure-heavy specialty.

Revenue is highly concentrated: the precomputed top 3 Medicare codes account for 72.4% of this provider’s Medicare revenue, with a single drug code dominating—J9271 alone represents 54.1% of the provider’s $1M in lifetime Medicare revenue ($541.8K). This concentration implies that changes in reimbursement or utilization for that product would materially move the provider’s Medicare revenue.

Payer mix is effectively single-payer on file: lifetime Medicare revenue is $1M and there is no Medicaid billing on file. The absence of Medicaid activity means the provider’s publicly available claims experience is driven entirely by Medicare beneficiaries, limiting visibility into other payer populations and creating reliance on one public payer class.

Competitive standing for the top drug and supportive drug differs: J9271 ranks #885 of 1841 nationally (52th percentile; typical, unremarkable volume) suggesting routine, not dominant, use of pembrolizumab relative to oncology peers; J0897 ranks #2331 of 10057 (77th percentile; typical, unremarkable volume), indicating relatively higher-than-average utilization of denosumab against a broad national mix but still described as typical. These rank/percentile positions imply the provider is not a national outlier for infusion volume overall, aside from visit-level E/M activity.

Office visit coding shows an atypically high intensity of follow-up care: 99215 accounts for 585 claims and $76.1K (7.6% of Medicare revenue) and ranks #1268 of 145531 nationally (99th percentile; extreme outlier, far above typical national volume for this code). This extreme outlier status for high-level established-patient visits suggests a caseload with complex decision-making or prolonged patient management that is well above typical peers.

Several supportive infusion and procedure codes have high claim counts but low per-claim reimbursement, for example J1439 (28.5K claims, $28.5K revenue) and J0881 (12.3K claims, $24.6K revenue), each reflecting low average paid/claim amounts. The presence of many low-dollar, high-count codes alongside high-dollar immunotherapy indicates an operational mix that includes routine, low-reimbursement infusions or supply items in addition to high-cost biologics.

Radiation-delivery and advanced radiation-modality codes appear at low national percentiles (G6015 ranks #1304 of 1429, 8th percentile; G6012 ranks #808 of 868, 7th percentile), which is consistent with a practice focused on medical oncology/intravenous therapies rather than in-house radiation treatment services. This supports the interpretation that the provider’s revenue stream is driven by systemic therapy administration and office-based management rather than radiation oncology.

The provider has a long-tenured NPI (enumerated 2005-07-15, ~21 years ago), indicating an established practice history. Coupled with the $1M lifetime Medicare revenue and concentrated drug-driven revenue mix, this suggests an experienced oncology clinician operating a modestly sized Medicare-facing practice with concentrated exposure to a small number of high-revenue drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

48 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	12,600	$40	$541.8K
J0897	Injection, denosumab, 1 mg	5,940	$20	$106.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	590	$130	$76K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,680	$40	$60.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	300	$130	$38.7K
J1439	Injection, ferric carboxymaltose, 1 mg	28,500	$1	$28.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	310	$90	$28.2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	12,320	$1	$24.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	240	$100	$23.7K
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	40	$260	$11.1K

Showing 1–10 of 48

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 48 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Ronald Kubica — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

48 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	10	9,400	$40	$469.6K
J0897	14	50	3,150	$20	$113.2K
J1569	1	10	1,430	$40	$51.3K
G6015	6	10	70	$260	$49.4K
J0881	3	10	12,320	$1	$31.2K
J9217	2	20	180	$130	$23.4K
J1439	4	10	25,500	$1	$23.1K
96413	12	40	170	$90	$17.7K
J3490	14	20	40	$150	$16.7K
G6012	4	10	80	$170	$16.5K

Showing 1–10 of 48

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ronald Kubica, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Littleton Hospital Association	NH	Critical Access Hospital	$0	$5.2M
New Mexico Oncology Hematology Consultants, Ltd.	NM	Hematology & Oncology Physician	$0	$4.2M
Littleton Hospital Association	NH	Rural Health Clinic/Center	$0	$3.4M
Gregg Franklin	NM	Radiation Oncology Physician	$2.5M	$0
Scott Stoerner	NM	Rheumatology Physician	$1.5M	$0
Shaya Ansari	NY	Diagnostic Radiology Physician	$1.5M	$1K
Pranshu Bansal	AZ	Hematology & Oncology Physician	$1.4M	$0
Annette Fontaine	NM	Medical Oncology Physician	$918.5K	$0
Mrunal Tailor	NM	Diagnostic Radiology Physician	$897.5K	$0

Nearby Providers

Other providers in the same ZIP code as Ronald Kubica, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Presbyterian Healthcare Services	NM	Internal Medicine Physician	$0	$240.8M
Heritage Home Healthcare Services, Inc.	NM	Home Health Agency	$0	$141.5M
Home Medical Equipment Specialists LLC	NM	Durable Medical Equipment & Medical Supplies	$0	$100M
The New Beginnings LLC	NM	Adult Day Care Clinic/Center	$0	$85.1M
We Care Agency, Inc.	NM	In Home Supportive Care Agency	$0	$60.1M
Lovelace Health System, LLC	NM	General Acute Care Hospital	$0	$57.7M
Adelante Development Center, Inc.	NM	Personal Care Attendant	$0	$57M
Eye Associates Of New Mexico Ltd	NM	Ophthalmology Physician	$0	$46.9M
Southwest Labs LLC	NM	Clinical Medical Laboratory	$1.1M	$41.5M
Southwest Medical Associates, LLC	NM	General Practice Physician	$0	$41.4M

Ronald Kubica — Billing Profile & Reimbursement Data

Sign up for Ronald Kubica — Billing Profile & Reimbursement Data policy alerts

Ronald Kubica — Billing Profile & Reimbursement Data

Sign up for Ronald Kubica — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References